Wednesday, pharmaceutical company Medicines Co. (MDCO) reported a decline in second quarter earnings from a year ago despite top line growth, owing to higher expenses.
The Parsippany, New Jersey-based Medicines second-quarter net income dipped to $3.8 million or $0.07 per share from $4.1 million or $0.08 per share in the same quarter last year. On average, five analysts polled by Thomson Reuters expected the company to report $0.05 per share. Analysts' estimates typically exclude the special items.
On a non-GAAP basis, net income was $12.3 million or $0.24 per share, down compared to $14.5 million or $0.28 per share a year ago.
Net revenue rose 20% to $104.2 million in the quarter from $86.7 million a year ago, yet falling short of analysts estimate of $106.60 million.
Angiomax U.S. sales increased by 17% to $98.8 million in the quarter, compared to $84.5 million a year ago. Angiomax/Angiox international net revenue surged 96% to $4.5 million from $2.3 million in the prior-year period.
Operating expenses increased to $98.05 million in the quarter from $80.51 million a yer ago.
Net income for the first six months of 2009 was $0.5 million or $0.01 per share, compared to net income of $8.9 million or $0.17 per share in the first six months of 2008.
The company reported non-GAAP net income of $15.5 million or $0.29 per share, for the first six months of 2009, compared to non-GAAP net income of $26.9 million or $0.51 per share a year ago. Non-GAAP net income excludes the Targanta acquisition, stock-based compensation expense and non-cash income taxes.
Total revenues for the first six months improved to $203.39 million from $166.16 million last year.
MDCO is trading at $8.40, up $0.01 or 0.12% on a volume of about 442 thousand shares.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.